Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Current Deferred Revenue (2020 - 2025)

Maravai Lifesciences Holdings has reported Current Deferred Revenue over the past 6 years, most recently at $1.6 million for Q2 2025.

  • Quarterly results put Current Deferred Revenue at $1.6 million for Q2 2025, down 23.63% from a year ago — trailing twelve months through Jun 2025 was $1.6 million (down 23.63% YoY), and the annual figure for FY2024 was $2.4 million, down 56.82%.
  • Current Deferred Revenue for Q2 2025 was $1.6 million at Maravai Lifesciences Holdings, down from $2.8 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for MRVI hit a ceiling of $120.7 million in Q1 2021 and a floor of $1.6 million in Q2 2025.
  • Median Current Deferred Revenue over the past 5 years was $4.5 million (2022), compared with a mean of $20.3 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 96.94% in 2022 and later skyrocketed 104.58% in 2024.
  • Maravai Lifesciences Holdings' Current Deferred Revenue stood at $10.2 million in 2021, then plummeted by 52.99% to $4.8 million in 2022, then rose by 14.58% to $5.5 million in 2023, then plummeted by 56.82% to $2.4 million in 2024, then tumbled by 30.99% to $1.6 million in 2025.
  • The last three reported values for Current Deferred Revenue were $1.6 million (Q2 2025), $2.8 million (Q1 2025), and $2.4 million (Q4 2024) per Business Quant data.